Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMMO75G)

• Drug Name: B-Octylglucoside Drug Info
• Synonyms: 29836-26-8; Octyl-beta-D-glucopyranoside; OCTYL BETA-D-GLUCOPYRANOSIDE; Octyl beta-D-glucoside; Octyl glucoside; Octyl b-D-Glucopyranoside; n-Octyl-beta-D-Glucoside; 1-O-n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-glucoside; beta-D-Octyl glucoside; 1-O-Octyl-beta-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(octyloxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-V109WUT6RL; n-Octyl glucoside; n-Octyl-beta-D-glucopyranoside; Octyl-beta-D-Glucopyranose; Octyl; V109WUT6RL

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 62852
  ChEBI ID: CHEBI:41128
  CAS Number: CAS 29836-26-8
  TTD Drug ID: DMMO75G

Molecule-Related Drug Atlas

Drug(s) Targeting Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Artemisinin	DMOY7W3	Malaria	1F40-1F45	Approved	[2]
Leflunomide	DMR8ONJ	Arthritis	FA20	Approved	[3]
Teriflunomide	DMQ2FKJ	Hyperlipidaemia	5C80	Approved	[4]
Atovaquone	DMY4UMW	Fungal infection	1F29-1F2F	Approved	[5]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[6]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[7]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[1]
1,4-Naphthoquinone	DMTCMH7	Discovery agent	N.A.	Investigative	[6]
Dihydroorotate	DM76BGZ	Discovery agent	N.A.	Investigative	[8]

Drug(s) Targeting Nitric-oxide synthase inducible (NOS2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Curcumin	DMQPH29	Solid tumour/cancer	2A00-2F9Z	Phase 3	[9]
SD-6010	DM9DEYL	Osteoarthritis	FA00-FA05	Phase 3	[10]
MPL-S	DMNDCFY	Endotoxic shock	1G41	Phase 3	[11]
Pimagedine HCl	DMPWH30	Diabetic kidney disease	GB61.Z	Phase 2/3	[12]
GW274150	DMZMCB1	Asthma	CA23	Phase 2	[13]
BXT-51072	DMD8GNB	Cardiovascular disease	BA00-BE2Z	Phase 2	[14]
HP-228	DMNZ35F	Postoperative pain	MG30-MG3Z	Phase 2	[15]
CR-3294	DMHJEZS	Diarrhea	ME05.1	Phase 2	[16]
KD-7040	DME1WV2	Pain	MG30-MG3Z	Phase 2	[17]
LT-1951	DM5N04G	Coronary artery disease	BA80	Phase 1/2	[18]

Drug(s) Targeting Rhodopsin (RHO)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alpha-D-Mannose	DMF5DLW	Discovery agent	N.A.	Investigative	[1]
L-serine-O-phosphate	DMTJ1NH	Discovery agent	N.A.	Investigative	[1]
Phosphonothreonine	DMTFHPI	Discovery agent	N.A.	Investigative	[1]
Beta-D-Mannose	DMHIG9K	Discovery agent	N.A.	Investigative	[1]
Hexadecanoic acid	DMWUXDZ	Discovery agent	N.A.	Investigative	[1]
NSC-88915	DM9WIHJ	Solid tumour/cancer	2A00-2F9Z	Investigative	[19]
Lauryl Dimethylamine-N-Oxide	DM3W2OE	Discovery agent	N.A.	Investigative	[1]
B-2-Octylglucoside	DMEGX8H	Discovery agent	N.A.	Investigative	[1]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[1]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[20]

Drug(s) Targeting Group IIA phospholipase A2 (GIIA sPLA2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
KH064	DMR1NYF	Breast cancer	2C60-2C65	Clinical trial	[21]
Lauric Acid	DM9C8KQ	Discovery agent	N.A.	Investigative	[1]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[20]
2-(4-phenoxyphenoxy)ethanamine	DM7TBUJ	Discovery agent	N.A.	Investigative	[22]
CACOSPONGIONOLIDE	DMIPJUS	Discovery agent	N.A.	Investigative	[23]
Elaidoylamide	DMP8VDT	Discovery agent	N.A.	Investigative	[1]
Cacospongionolide E	DM2DYAV	Discovery agent	N.A.	Investigative	[23]
N-Tridecanoic Acid	DMNZ37C	Discovery agent	N.A.	Investigative	[20]
CACOSPONGIONOLIDE B	DMCSXNW	Discovery agent	N.A.	Investigative	[23]
BOLINAQUINONE	DMVB6UG	Discovery agent	N.A.	Investigative	[24]

Drug(s) Targeting Steryl-sulfatase (STS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tranilast	DME5Y64	Allergic rhinitis	CA08.0	Approved	[25]
Coumate	DMVKW0N	Breast cancer	2C60-2C65	Phase 2	[26]
STX-140	DMJK5CT	Osteoporosis	FB83.0	Phase 2	[27]
PGL-2001	DMKA705	Endometriosis	GA10	Phase 2	[28]
PGL-2	DMJTYO4	Endometriosis	GA10	Phase 2	[28]
STX 64	DMJAPRK	Prostate cancer	2C82.0	Phase 1	[29]
EMATE	DMFQX1U	Discovery agent	N.A.	Investigative	[30]
Sulfamic acid 2-nonyl-4-oxo-4H-chromen-6-yl ester	DMM70K1	Discovery agent	N.A.	Investigative	[31]
Estradiol 17-O-sulfamate	DM7K14V	Discovery agent	N.A.	Investigative	[27]
4-Sulfamoyloxy-benzoic acid pentyl ester	DMZIFW7	Discovery agent	N.A.	Investigative	[32]

Drug(s) Targeting Glucocorticoid receptor (NR3C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Dexamethasone	DMMWZET	Acute adrenal insufficiency		Approved	[33]
Hydrocortisone	DMGEMB7	Acne vulgaris	ED80	Approved	[34]
Prednisolone	DMQ8FR2	Acute adrenal insufficiency		Approved	[35]
Fluticasone	DMGCSVF	Allergic rhinitis	CA08.0	Approved	[36]
Betamethasone Valerate	DMMIAXO	Dermatological disease	DA24.Y	Approved	[34]
Methylprednisolone	DM4BDON	Acute adrenal insufficiency		Approved	[34]
Deflazacort	DMV0RNS	Duchenne dystrophy	8C70	Approved	[34]
Prednisone	DM2HG4X	Acute asthma	CA23	Approved	[37]
Budesonide	DMJIBAW	Allergic rhinitis	CA08.0	Approved	[38]
Mifepristone	DMGZQEF	Cushing disease	5A70	Approved	[39]

Drug(s) Targeting Gastric triacylglycerol lipase (LIPF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cetilistat	DMWAHTN	Diabetic complication	5A2Y	Phase 3	[40]
Undecyl-Phosphinic Acid Butyl Ester	DMD9KEB	Discovery agent	N.A.	Investigative	[20]

Drug(s) Targeting Plasmodium Cytochrome B (Malaria MT-CYB)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
B-2-Octylglucoside	DMEGX8H	Discovery agent	N.A.	Investigative	[1]
UBIQUINONE-2	DMLUP30	Discovery agent	N.A.	Investigative	[20]
5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole	DM74JL8	Discovery agent	N.A.	Investigative	[20]
FAMOXADONE	DMJYNMC	Discovery agent	N.A.	Investigative	[20]
2-NONYL-4-HYDROXYQUINOLINE N-OXIDE	DMQWR69	Discovery agent	N.A.	Investigative	[20]
5-heptyl-6-hydroxy-1,3-benzothiazole-4,7-dione	DM49F6Z	Discovery agent	N.A.	Investigative	[20]

Drug(s) Targeting Lanosterol synthase (LSS)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ZD-9720	DMFV47R	Arteriosclerosis	BD40	Terminated	[41]
BIBB-515	DM6QT9P	Arteriosclerosis	BD40	Terminated	[42]
BIBX-79	DMRXWCO	Arteriosclerosis	BD40	Terminated	[43]
Lanosterol	DMHN74V	Discovery agent	N.A.	Investigative	[1]
PMID22533316C1	DMYEMWB	Discovery agent	N.A.	Investigative	[44]
PMID22533316C4	DMW3UHO	Discovery agent	N.A.	Investigative	[44]
PMID9003518C4	DMYE64O	Discovery agent	N.A.	Investigative	[45]
29-methylidene-2,3-oxidosqualene	DMUQAP7	Discovery agent	N.A.	Investigative	[45]
Tetradecane	DMK8P61	Discovery agent	N.A.	Investigative	[1]
PMID9003518C3	DM1I578	Discovery agent	N.A.	Investigative	[45]

Drug(s) Targeting Prostaglandin G/H synthase 1 (COX-1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Salicyclic acid	DM2F8XZ	Acne vulgaris	ED80	Approved	[46]
Naproxen	DMZ5RGV	Bursitis		Approved	[47]
Mesalazine	DMOL5IU	Diverticulitis		Approved	[48]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[49]
Bromfenac	DMKB79O	Pain	MG30-MG3Z	Approved	[50]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[34]
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[51]
Piroxicam	DMTK234	Osteoarthritis	FA00-FA05	Approved	[34]
Suprofen	DMKXJZ7	Miosis	LA11.62	Approved	[52]
Gamma-Homolinolenic acid	DMSXKYG	Malnutrition	5B50-5B71	Approved	[53]

Drug(s) Targeting Stress-activated protein kinase 2a (p38 alpha)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ozagrel	DMIGKA1	Xerophthalmia	5B55.Y	Phase 4	[54]
Losmapimod	DMIL37Z	Acute coronary syndrome	BA41	Phase 3	[54]
VX-702	DMKJDR6	Coronary artery disease	BA80	Phase 2a	[55]
VX-745	DMJAEG6	Alzheimer disease	8A20	Phase 2	[56]
Dilmapimod	DMBYJ92	Acute lung injury	NB32.3	Phase 2	[54]
PMID25991433-Compound-A1	DM89LF0	N. A.	N. A.	Patented	[57]
PMID25991433-Compound-F2	DM37VIQ	N. A.	N. A.	Patented	[57]
PMID25991433-Compound-L2	DM58UO9	N. A.	N. A.	Patented	[57]
PMID25991433-Compound-L3	DM3LWUR	N. A.	N. A.	Patented	[57]
PMID25991433-Compound-L1	DM2135Y	N. A.	N. A.	Patented	[57]

Drug(s) Targeting Prostaglandin G/H synthase 2 (COX-2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[58]
Naproxen	DMZ5RGV	Bursitis		Approved	[47]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[59]
Indomethacin	DMSC4A7	Bursitis		Approved	[34]
Celecoxib	DM6LOQU	Dysmenorrhea	GA34.3	Approved	[60]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[61]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[62]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[63]
Eicosapentaenoic acid/docosa-hexaenoic acid	DMMUCG4	Hypertriglyceridemia	5C80.1	Approved	[49]
Aminosalicylic Acid	DMENSL5	Crohn disease	DD70	Approved	[34]

Drug(s) Targeting Mineralocorticoid receptor (MR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[64]
Eplerenone	DMF0NQR	Heart failure	BD10-BD13	Approved	[34]
Fludrocortisone	DMUDIR8	Addison disease	5A74.0	Approved	[65]
Desoxycorticosterone Acetate	DMS0AFE	Discovery agent	N.A.	Approved	[34]
Desoxycorticosterone Pivalate	DMSA4B3	Addison disease	5A74.0	Approved	[66]
Drospirenone	DM1A9W3	Acne vulgaris	ED80	Approved	[67]
Spironolactone	DM2AQ5N	Chronic heart failure	BD1Z	Approved	[34]
Finerenone	DMM4FJ3	Chronic kidney disease	GB61	Approved	[68]
ZK-91587	DMJ94L0	Cardiovascular disease	BA00-BE2Z	Phase 2	[69]
Nerenone	DMBJ3GL	Diabetic nephropathy	GB61.Z	Phase 2	[70]

Drug(s) Targeting PTPN1 messenger RNA (PTPN1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[71]
TRYPAN BLUE	DM4NTMO	Ophthalmic surgery injury	PK97	Approved	[72]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[73]
ISIS 113715	DMUPD4G	Type-2 diabetes	5A11	Phase 2	[74]
ISIS-PTP1Brx	DMJGVXT	Type-2 diabetes	5A11	Phase 2	[75]
ERTIPROTAFIB	DMJXEV7	Type-2 diabetes	5A11	Terminated	[76]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
Double Oxidized Cysteine	DM6TU84	Discovery agent	N.A.	Investigative	[1]
1,2-NAPHTHOQUINONE	DMYXELH	Discovery agent	N.A.	Investigative	[77]

Drug(s) Targeting Pancreatic triacylglycerol lipase (PNLIP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Orlistat	DMRJSP8	Obesity	5B81	Approved	[34]
Dalbavancin	DMGMNH3	Bacterial infection	1A00-1C4Z	Approved	[60]
Pancrecarb	DMOML9Q	Pancreatic malfunction	DC30-DC3Z	NDA filed	[78]
Liprotamase	DMNF4UH	Cystic fibrosis	CA25	Phase 3	[79]
MS-1819	DM35YFC	Exocrine pancreatic insufficiency	DC35.1	Phase 1/2	[80]
AZM-131	DMLCSRF	Obesity	5B81	Terminated	[81]
(Hydroxyethyloxy)Tri(Ethyloxy)Octane	DMY6FUD	Discovery agent	N.A.	Investigative	[1]
B-Nonylglucoside	DM48VJR	Discovery agent	N.A.	Investigative	[20]
METHOXYUNDECYLPHOSPHINIC ACID	DMY0O7X	Discovery agent	N.A.	Investigative	[20]
Daio-Orengedokuto (DOT)	DM3M652	Discovery agent	N.A.	Investigative	[82]

Drug(s) Targeting Influenza M2 protein (Influ M)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Amantadine	DMS3YE9	Influenza A virus infection	1E30	Approved	[83]
Rimantadine	DM5DWMU	Influenza A virus infection	1E30	Approved	[84]
TCN-032	DM9PVNJ	Influenza virus infection	1E30-1E32	Phase 2	[85]
Spiro[piperidine-2,2-adamantane]	DMWU9PV	Discovery agent	N.A.	Investigative	[86]
2-(1-adamantyl) piperidine	DM05OJD	Discovery agent	N.A.	Investigative	[86]
Rimantadine isomer 2	DM3BEF7	Discovery agent	N.A.	Investigative	[86]
2-(1-adamantyl) pyrrolidine	DMMSFEU	Discovery agent	N.A.	Investigative	[86]
3-(2-adamantyl) pyrrolidine	DMS98WA	Discovery agent	N.A.	Investigative	[86]
Spiro[pyrrolidine-2,2-adamantane]	DMW48JD	Discovery agent	N.A.	Investigative	[86]
2-(1-adamantyl)-2-methyl-pyrrolidine	DMIGRMV	Discovery agent	N.A.	Investigative	[86]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Apolipoprotein A-II (APOA2)	TTGQA9W	APOA2_HUMAN	Inhibitor	[1]
Gastric triacylglycerol lipase (LIPF)	TTKYZA9	LIPG_HUMAN	Inhibitor	[1]
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Inhibitor	[1]
Group IIA phospholipase A2 (GIIA sPLA2)	TTO8QRU	PA2GA_HUMAN	Inhibitor	[1]
Influenza M2 protein (Influ M)	TTXT3PU	M2_I34A1	Inhibitor	[1]
Lanosterol synthase (LSS)	TT7O8ZA	ERG7_HUMAN	Inhibitor	[1]
Mineralocorticoid receptor (MR)	TT26PHO	MCR_HUMAN	Inhibitor	[1]
Nitric-oxide synthase inducible (NOS2)	TTF10I9	NOS2_HUMAN	Inhibitor	[1]
Pancreatic triacylglycerol lipase (PNLIP)	TTXMY0J	LIPP_HUMAN	Inhibitor	[1]
Plasmodium Cytochrome B (Malaria MT-CYB)	TTRAMF0	CYB_PLAFA	Inhibitor	[1]
Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase)	TT3PQ2Y	PYRD_PLAF7	Inhibitor	[1]
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[1]
Prostaglandin G/H synthase 2 (COX-2)	TTVKILB	PGH2_HUMAN	Inhibitor	[1]
PTPN1 messenger RNA (PTPN1 mRNA)	TTELIN2	PTN1_HUMAN	Inhibitor	[1]
Rhodopsin (RHO)	TTH0KSX	OPSD_HUMAN	Inhibitor	[1]
Steryl-sulfatase (STS)	TTHM0R1	STS_HUMAN	Inhibitor	[1]
Stress-activated protein kinase 2a (p38 alpha)	TTQBR95	MK14_HUMAN	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] The fight against drug-resistant malaria: novel plasmodial targets and antimalarial drugs. Curr Med Chem. 2008;15(2):161-71.
• [3] Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases. Eur J Biochem. 1999 Dec;266(3):1184-91.
• [4] Expression and characterization of E. coli-produced soluble, functional human dihydroorotate dehydrogenase: a potential target for immunosuppression. J Mol Microbiol Biotechnol. 1999 Aug;1(1):183-8.
• [5] Inhibitor binding in a class 2 dihydroorotate dehydrogenase causes variations in the membrane-associated N-terminal domain. Protein Sci. 2004 Apr;13(4):1031-42.
• [6] Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid. Chem Biol Interact. 2000 Jan 3;124(1):61-76.
• [7] Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
• [8] Structure-activity relationships of pyrimidines as dihydroorotate dehydrogenase inhibitors. Biochem Pharmacol. 1988 Oct 15;37(20):3807-16.
• [9] A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
• [10] A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
• [11] Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
• [12] Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
• [13] GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
• [14] Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
• [15] HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
• [16] Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
• [17] WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
• [18] Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
• [19] Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. J Med Chem. 2008 Sep 11;51(17):5297-303.
• [20] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [21] D-Tyrosine as a chiral precusor to potent inhibitors of human nonpancreatic secretory phospholipase A2 (IIa) with antiinflammatory activity. Chembiochem. 2003 Mar 3;4(2-3):181-5.
• [22] Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching. J Med Chem. 2008 Dec 25;51(24):7882-8.
• [23] A new cacospongionolide inhibitor of human secretory phospholipase A2 from the Tyrrhenian sponge Fasciospongia cavernosa and absolute configuration... J Nat Prod. 1998 Jul;61(7):931-5.
• [24] New sesquiterpene derivatives from the sponge Dysidea species with a selective inhibitor profile against human phospholipase A2 and other leukocyte... J Nat Prod. 2001 May;64(5):612-5.
• [25] Review of estrone sulfatase and its inhibitors--an important new target against hormone dependent breast cancer. Curr Med Chem. 2002 Jan;9(2):263-73.
• [26] Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
• [27] 2-substituted estradiol bis-sulfamates, multitargeted antitumor agents: synthesis, in vitro SAR, protein crystallography, and in vivo activity. J Med Chem. 2006 Dec 28;49(26):7683-96.
• [28] Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age. Reprod Sci. 2014 Oct;21(10):1256-65.
• [29] Phase I study of STX 64 (667 Coumate) in breast cancer patients: the first study of a steroid sulfatase inhibitor. Clin Cancer Res. 2006 Mar 1;12(5):1585-92.
• [30] Thiosemicarbazones of formyl benzoic acids as novel potent inhibitors of estrone sulfatase. J Med Chem. 2007 Jul 26;50(15):3661-6.
• [31] Estrogenic potential of 2-alkyl-4-(thio)chromenone 6-O-sulfamates: potent inhibitors of human steroid sulfatase. J Med Chem. 2003 Nov 6;46(23):5091-4.
• [32] Inhibition of estrone sulfatase (ES) by alkyl and cycloalkyl ester derivatives of 4-[(aminosulfonyl)oxy] benzoic acid. Bioorg Med Chem Lett. 2004 Feb 9;14(3):605-9.
• [33] Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
• [34] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [35] Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
• [36] Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
• [37] Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
• [38] PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
• [39] The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
• [40] Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond). 2007 Mar;31(3):494-9.
• [41] Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
• [42] Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
• [43] Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58.
• [44] Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002.
• [45] Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9.
• [46] The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb Haemost. 2008 Jul;100(1):70-5.
• [47] Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol. 2000 Oct;40(10):1109-20.
• [48] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [49] Cox-2 inhibitory effects of naturally occurring and modified fatty acids. J Nat Prod. 2001 Jun;64(6):745-9.
• [50] Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006 Jun;22(6):1133-40.
• [51] Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
• [52] Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
• [53] Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. Biochem J. 2002 Jul 15;365(Pt 2):489-96.
• [54] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [55] Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. Arthritis Rheum. 2009 May;60(5):1232-41.
• [56] Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci. 2002 Jan;23(1):40-5.
• [57] c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
• [58] Maternal toxicity of nonsteroidal anti-inflammatory drugs as an important factor affecting prenatal development. Reprod Toxicol. 2009 Sep;28(2):239-44.
• [59] Membranous nephropathy associated with the relatively selective cyclooxygenase-2 inhibitor, etodolac, in a patient with early rheumatoid arthritis. Intern Med. 2007;46(13):1055-8.
• [60] Pfizer. Product Development Pipeline. March 31 2009.
• [61] Renal effects of nabumetone, a COX-2 antagonist: impairment of function in isolated perfused rat kidneys contrasts with preserved renal function in vivo. Exp Nephrol. 2001;9(6):387-96.
• [62] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [63] Flurbiprofen, a cyclooxygenase inhibitor, protects mice from hepatic ischemia/reperfusion injury by inhibiting GSK-3 signaling and mitochondrial permeability transition.Mol Med.2012 Sep 25;18:1128-35.
• [64] Stimulation of testosterone production in rat Leydig cells by aldosterone is mineralocorticoid receptor mediated. Mol Cell Endocrinol. 2005 Nov 24;243(1-2):35-42.
• [65] Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
• [66] Characterization of rat brain aldosterone receptors reveals high affinity for corticosterone. Endocrinology. 1983 Dec;113(6):2043-51.
• [67] Biochemical mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001-2004: mechanisms leading to optimal efficacy and ... Curr Top Med Chem. 2006;6(5):461-78.
• [68] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [69] ZK91587: a novel synthetic antimineralocorticoid displays high affinity for corticosterone (type I) receptors in the rat hippocampus. Life Sci. 1988;43(19):1537-43.
• [70] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 626).
• [71] Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
• [72] Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
• [73] Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
• [74] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [75] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [76] 2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60.
• [77] Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1941-6.
• [78] Clinical pipeline report, company report or official report of Digestive Care.
• [79] Clinical pipeline report, company report or official report of Anthera Pharmaceuticals.
• [80] Clinical pipeline report, company report or official report of AzurRx.
• [81] US patent application no. 7217,697, Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor.
• [82] Daio-Orengedokuto inhibits HMG-CoA reductase and pancreatic lipase. Biol Pharm Bull. 2002 Nov;25(11):1442-5.
• [83] Discovery of spiro-piperidine inhibitors and their modulation of the dynamics of the M2 proton channel from influenza A virus. J Am Chem Soc. 2009 Jun 17;131(23):8066-76.
• [84] Antiviral resistance of influenza A (H3N2) strains isolated in northern Greece between 2004 and 2007. Euro Surveill. 2009 Jan 29;14(4). pii: 19104.
• [85] Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci U S A. 2010 July 13; 107(28): 12658-12663.
• [86] Antiviral agents active against influenza A viruses. Nat Rev Drug Discov. 2006 Dec;5(12):1015-25.